Kaiku Health Expands Partnership With Novartis

Last year Kaiku Health announced its collaboration with Novartis in developing digital patient monitoring and management for melanoma patients. Following the success of the collaboration, Kaiku Health and Novartis are now expanding it into a partnership.

In the first phase of the collaboration, Kaiku Health and Novartis developed a therapy-specific module for patients receiving Tafinlar® (dabrafenib) and Mekinist® (trametinib) combination targeted therapies for adjuvant, unresectable or metastatic melanoma with BRAF mutation. The goal was to generate novel insights on patient outcomes in a real-world setting and to develop more advanced machine learning based algorithms, such as symptom prediction, for personalising the symptom management of patients receiving Tafinlar and Mekinist, and other BRAF and MEK combination therapies.

Read more about the expanded partnership here.